Bavarian Nordic Past Earnings Performance
Past criteria checks 2/6
Bavarian Nordic has been growing earnings at an average annual rate of 27.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 45.4% per year. Bavarian Nordic's return on equity is 14.3%, and it has net margins of 20.9%.
Key information
27.6%
Earnings growth rate
28.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 45.4% |
Return on equity | 14.3% |
Net Margin | 20.9% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Bavarian Nordic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 7,062 | 1,475 | 751 | 2,228 |
30 Sep 23 | 5,906 | 723 | 721 | 1,757 |
30 Jun 23 | 5,533 | 1,076 | 666 | 1,695 |
31 Mar 23 | 4,083 | 301 | 630 | 1,376 |
31 Dec 22 | 3,151 | -347 | 589 | 1,183 |
30 Sep 22 | 2,404 | -599 | 509 | 755 |
30 Jun 22 | 1,849 | -693 | 484 | 470 |
31 Mar 22 | 1,683 | -606 | 476 | 382 |
31 Dec 21 | 1,898 | -465 | 485 | 399 |
30 Sep 21 | 1,583 | -737 | 502 | 409 |
30 Jun 21 | 1,693 | -629 | 542 | 437 |
31 Mar 21 | 2,022 | -368 | 561 | 397 |
31 Dec 20 | 1,852 | 278 | 564 | 341 |
30 Sep 20 | 1,914 | 606 | 488 | 325 |
30 Jun 20 | 1,499 | 481 | 398 | 314 |
31 Mar 20 | 901 | 267 | 303 | 350 |
31 Dec 19 | 662 | -347 | 227 | 387 |
30 Sep 19 | 554 | -402 | 217 | 398 |
30 Jun 19 | 631 | -271 | 211 | 379 |
31 Mar 19 | 616 | -279 | 215 | 373 |
31 Dec 18 | 501 | -362 | 214 | 386 |
30 Sep 18 | 360 | -445 | 218 | 422 |
30 Jun 18 | 873 | -151 | 209 | 511 |
31 Mar 18 | 1,184 | 5 | 206 | 535 |
31 Dec 17 | 1,370 | 181 | 208 | 518 |
30 Sep 17 | 1,745 | 453 | 205 | 512 |
30 Jun 17 | 1,463 | 225 | 214 | 482 |
31 Mar 17 | 1,182 | 153 | 211 | 459 |
31 Dec 16 | 1,007 | 31 | 213 | 463 |
30 Sep 16 | 909 | -54 | 215 | 402 |
30 Jun 16 | 536 | -202 | 204 | 349 |
31 Mar 16 | 808 | -115 | 205 | 373 |
31 Dec 15 | 1,021 | 59 | 217 | 375 |
30 Sep 15 | 1,244 | 155 | 229 | 462 |
30 Jun 15 | 1,390 | 186 | 244 | 507 |
31 Mar 15 | 1,166 | 70 | 242 | 496 |
31 Dec 14 | 1,217 | 26 | 226 | 479 |
30 Sep 14 | 1,013 | -99 | 204 | 425 |
30 Jun 14 | 1,107 | -61 | 198 | 406 |
31 Mar 14 | 1,293 | -12 | 198 | 512 |
31 Dec 13 | 1,213 | -47 | 198 | 497 |
30 Sep 13 | 1,142 | -82 | 221 | 501 |
30 Jun 13 | 1,127 | -81 | 215 | 479 |
Quality Earnings: BVNK.F has a large one-off loss of DKK634.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: BVNK.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BVNK.F has become profitable over the past 5 years, growing earnings by 27.6% per year.
Accelerating Growth: BVNK.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BVNK.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: BVNK.F's Return on Equity (14.3%) is considered low.